Board

CEO
Sven Rohmann

CEO since 2025. Dr. Sven Rohmann has a long track record in the pharmaceutical and biotechnology industry. As CEO of the Swedish immuno-oncology company Oasmia, he led capital raising for and the launch of Apealea, a pioneering treatment against ovarian cancer. The drug was launched in Sweden, Denmark and Finland at the beginning of 2020 and was subsequently out-licensed to the American company Elevar Therapeutics. Dr. Rohmann was also the founder and CEO of Ganymed Pharmaceuticals, where he took the company’s lead drug candidate IMAB362 from discovery to clinical phase II. Ganymede was later acquired by Astellas. Earlier in his career, he was CEO of BioVision, which under his leadership was acquired by Digilab Inc.

Sven does not own any shares in the company. Independent in relation to the company and its senior executives. Independent in relation to major shareholders.

 

Chairman

Helge Trettö Olsen

Chairman since 2025.

Helge does not own any shares in the company. Independent in relation to the company and its senior executives. Independent in relation to major shareholders.

 

Board members

Vidar Osen

Board member since 2025.

Vidar does not own any shares in the company. Independent in relation to the company and its senior executives. Independent in relation to major shareholders.

 

Robert Simmons

Board member since 2025.

Robert does not own any shares in the company. Independent in relation to the company and its senior executives. Independent in relation to major shareholders.